The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial
Open accessAbstract
BackgroundTreatment for pancreatic cancer with pharmacological ascorbate (ascorbic acid, vitamin C) decreases tumor progression in preclinical models. A phase I clinical trial was performed to establish safety and tolerability of pharmacological ascorbate combined with gemcitabine in patients with biopsy-proven stage IV pancreatic adenocarcinoma.DesignNine subjects received twice-weekly intravenous ascorbate (15–125 g) employing Simon’s accelerated titration design to achieve a targeted post-infusion plasma level of ≥350 mg/dL (≥20 mM). Subjects received concurrent gemcitabine. Disease burden, weight, performance status, hematologic and metabolic laboratories, time to progression and overall survival were monitored.ResultsMean plasma ascorbate trough levels were significantly higher than baseline (1.46 ± 0.02 vs. 0.78 ± 0.09 mg/dL, i.e., 83 vs. 44 μM, p < 0.001). Adverse events attributable to the drug combination were rare and included diarrhea (n = 4) and dry mouth (n = 6). Dose-limiting criteria were not met for this study. Mean survival of subjects completing at least two cycles (8 weeks) of therapy was 13 ± 2 months.ConclusionsData suggest pharmacologic ascorbate administered concurrently with gemcitabine is well tolerated. Initial data from this small sampling suggest some efficacy. Further studies powered to determine efficacy should be conducted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Schafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587
Self-citationSiegel, R., Ward, E., Brawley, O., & Jemal, A. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20121 · Cited by 4,070
Morrow, J. D., Hill, K. E., Burk, R. F., Nammour, T. M., Badr, K. F., & Roberts, L. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9383 · Cited by 1,899
Self-citationVitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3704 · Cited by 1,325
Self-citationChen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075 · cited 1×
“At these high levels, pharmacological ascorbate has been proposed as a pro-drug for the delivery of H2O2 to tumors [7].”
BackgroundSelf-citationVitamin C pharmacokinetics: Implications for oral and intravenous use
Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00010 · Cited by 992
Self-citationCatalytic Metals, Ascorbate and Free Radicals: Combinations to Avoid
Buettner, G. R., & Jurkiewicz, B. A. (1996) · Radiation Research · doi:10.2307/3579271 · Cited by 887
Self-citation
Cited by
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007154 · Cited by 501
Self-citationSchoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.018 · Cited by 443
Self-citationTorti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426
The isoprostanes—25 years later
Milne, G. L., Dai, Q., & Roberts, L. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.10.007 · Cited by 335
Self-citationDoskey, C. M., Buranasudja, V., Wagner, B. A., Wilkes, J. G., Du, J., Cullen, J. J., & Buettner, G. R. (2016) · Redox Biology · doi:10.1016/j.redox.2016.10.010 · Cited by 300
Self-citationPotential Mechanisms of Action for Vitamin C in Cancer: Reviewing the Evidence
Vissers, M. C. M., & Das, A. B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00809 · Cited by 188
“, 2016) and recent phase I trials have indicated that high-dose vitamin C is a useful adjunct to chemotherapy (Welsh et al., 2013; Hoffer et al., 2015).”
InfluentialThe Role of Iron in Cancer Progression
Guo, Q., Li, L., Hou, S., Yuan, Z., Li, C., Zhang, W., Zheng, L., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.778492 · Cited by 150
Intravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge
Carr, A. C., & Cook, J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01182 · Cited by 133
Intravenous Vitamin C and Cancer: A Systematic Review
Fritz, H., Flower, G., Weeks, L., Cooley, K., Callachan, M., McGowan, J., Skidmore, B., Kirchner, L., & Seely, D. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414534463 · Cited by 124
“We included controlled and uncontrolled studies; controlled studies had to compare patients with cancer receiving IVC to patients with cancer not receiving IVC.”
BackgroundMethodResultInfluentialPharmacological Ascorbate Radiosensitizes Pancreatic Cancer
Du, J., Cieslak, J. A., Welsh, J. L., Sibenaller, Z. A., Allen, B. G., Wagner, B. A., Kalen, A. L., Doskey, C. M., Strother, R. K., Button, A. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1707 · Cited by 112
“In a phase I clinical trial that investigated the use of pharmacologic ascorbate as an adjuvant to gemcitabine, the standard of care, in the treatment of pancreatic cancer, it was well-tolerated with few dose-limiting toxicities (49).”
Self-citationMyths, Artifacts, and Fatal Flaws: Identifying Limitations and Opportunities in Vitamin C Research
Michels, A., & Frei, B. (2013) · Nutrients · doi:10.3390/nu5125161 · Cited by 111
Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials
Nauman, G., Gray, J. C., Parkinson, R., Levine, M., & Paller, C. J. (2018) · Antioxidants · doi:10.3390/antiox7070089 · Cited by 107
Self-citationThe effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life
Carr, A. C., Vissers, M. C. M., & Cook, J. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00283 · Cited by 104
Toyokuni, S. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.401 · Cited by 96
Intravenous vitamin C in the supportive care of cancer patients: A review and rational approach
Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018) · Current Oncology · doi:10.3747/co.25.3790 · Cited by 99
Ma, E., Chen, P., Wilkins, H. M., Wang, T., Swerdlow, R. H., & Chen, Q. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.008 · Cited by 79
Manganoporphyrins Increase Ascorbate-Induced Cytotoxicity by Enhancing H2O2 Generation
Rawal, M., Schroeder, S. R., Wagner, B. A., Cushing, C. M., Welsh, J. L., Button, A. M., Du, J., Sibenaller, Z. A., Buettner, G. R., & Cullen, J. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0470 · Cited by 78
“ing this plasma [AscH ] is central to cytotoxic AscH therapy (4, 8, 10).”
Self-citationCampbell, E. J., Vissers, M. C. M., Wohlrab, C., Hicks, K. O., Strother, R. M., Bozonet, S. M., Robinson, B. A., & Dachs, G. U. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.08.027 · Cited by 67
Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
Xia, J., Xu, H., Zhang, X., Allamargot, C., Coleman, K. L., Nessler, R., Frech, I., Tricot, G., & Zhan, F. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.011 · Cited by 63
“Recently, reports have shown that pharmacologically dosed ascorbic acid (PAA) 50–100 g (Chen et al., 2008; Padayatty et al., 2004; Hoffer et al., 2008; Padayatty et al., 2006; Welsh et al., 2013), administered intravenously, has potent anti-cancer activity and its role as anti-cancer therapy is being studied at the Un…”
BackgroundCampbell, E. J., Dachs, G. U., Morrin, H. R., Davey, V. C., Robinson, B. A., & Vissers, M. C. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5503-x · Cited by 63
Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions
Bargiela, D., Burr, S. P., & Chinnery, P. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.02.002 · Cited by 60
Pharmacokinetic modeling of ascorbate diffusion through normal and tumor tissue
Kuiper, C., Vissers, M. C. M., & Hicks, K. O. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.09.023 · Cited by 45
Wilkes, J. G., O’Leary, B. R., Du, J., Klinger, A. R., Sibenaller, Z. A., Doskey, C. M., Gibson-Corley, K. N., Alexander, M. S., Tsai, S., Buettner, G. R., et al. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9876-z · Cited by 36
Self-citationJóźwiak, P., Ciesielski, P., Zaczek, A., Lipińska, A., Pomorski, L., Wieczorek, M., Bryś, M., Forma, E., & Krześlak, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0388-y · Cited by 31
Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model
Serrano, O. K., Parrow, N. L., Violet, P.-C., Yang, J., Zornjak, J., Basseville, A., & Levine, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.032 · Cited by 29
Self-citationThe interplay between vitamin C and thyroid
Farasati Far, B., Behnoush, A. H., Ghondaghsaz, E., Habibi, M. A., & Khalaji, A. (2023) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.432 · Cited by 23
Metadata
- Authors
- Welsh, J. L., Wagner, B. A., van’t Erve, T. J., Zehr, P. S., Berg, D. J., Halfdanarson, T. R., Yee, N. S., Bodeker, K. L., Du, J., Roberts, L. J., Drisko, J., Levine, M., Buettner, G. R., & Cullen, J. J.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2013-02-05
- Volume
- 71
- Issue
- 3
- Pages
- 765-775
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W1990035048
- Cited by
- 310
- References
- 25
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.